Company intelligence / Profile preview
4D Molecular Therapeutics
Emeryville, California, United States4dmoleculartherapeutics.com ↗
- Ownership
- Public · FDMT
- Employees
- ~150
- Development stage
- Phase 3
01
Overview
The company’s lead program, 4D-150 for wet AMD and DME, has received RMAT designation from the FDA in both indications. It has shown sustained visual acuity improvements with reduced treatment burden. The second key program, 4D-710 for cystic fibrosis lung disease, demonstrated successful delivery and expression of the CFTR transgene via aerosolized administration. Both are advancing toward pivotal Phase 3 trials with regulatory alignment on trial design. Early-stage rare disease programs have been discontinued to focus resources on these two late-stage assets.
- Therapeutic areas
- OphthalmologyPulmonology
- Modalities
- Adeno-associated virus (AAV) gene therapy vectorsgenetic medicines
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →03
Partnerships
F. Hoffmann-La Roche Ltd/Roche – ophthalmology AAV products development/commercialization partnershipPfizer – cardiac AAV vector discovery/development collaboration and equity investmentArbor Biotechnologies – CRISPR/Cas-based therapeutic candidate collaboration initiated in January 2024Other past partners include uniQure, AGTC, Benitec
04
Financials
- Market cap
- $741.3M
- Total revenue
- $3.8M
- Enterprise value
- $419.2M
Beyond the preview
Go deeper on 4D Molecular Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4D Molecular Therapeutics.